医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KCI Brings Enhanced Negative Pressure Wound Therapy System to Japan

2013年04月10日 AM08:25
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Kinetic Concepts, Inc. today announced that its ActiV.A.C.® Therapy System is now available for in-patient use in Japan. The ActiV.A.C.® Therapy System, a lightweight, portable negative pressure therapy system, includes many enhancements that make using V.A.C.® Therapy simple for both patients and physicians while delivering improved clinical outcomes.

“As the negative pressure wound therapy pioneer in Japan and the rest of the world, we are committed to providing innovative healing technologies to the Japanese medical community,” said Joe Woody, president & CEO, KCI. “We also deliver gold standard service and the clinical evidence and support physicians need to improve patient lives.”

The newly approved system provides proven clinical outcomes based on T.R.A.C.™ Technology which monitors and maintains prescribed pressure at the wound site. T.R.A.C.™ Technology ensures optimal perfusion and oxygen is delivered to the wound site and helps ensure patient safety.

“The ActiV.A.C.® Therapy System is now available to patients in Japan. It provides the same T.R.A.C.™ Technology as the V.A.C. ATS® Therapy System, but is more sophisticated, technically improved and most importantly portable,” said Dr. Masato Kurokawa, Director of Plastic Surgery, Takarazuka City Hospital, Hyogo, Japan. “Based on substantial clinical evidence from around the world, I am confident that the ActiV.A.C.® System will provide outstanding healing results.”

The ActiV.A.C.® Therapy System is lightweight (1.08 Kg) and portable which is a significant enhancement to the current KCI product offering in Japan. The new ActiV.A.C.® Therapy System provides tremendous benefits for patients in Japan, providing mobility during relatively long stays in the hospital and significantly improving quality of life during the recovery phase.

“KCI understands that innovation alone is not enough to change clinical practice and patient outcomes, which is why we provide extensive clinical training and support services,” said Mike Mathews, SVP, International, KCI. “Based on our extensive experience of the ActiV.A.C.® Therapy System, we believe that this product is the best choice in NPWT in Japan, ensuring optimal patient safety while delivering proven clinical outcomes.”

KCI KK introduced the first negative pressure technology product, the V.A.C. ATS® Therapy System, to Japan in April 2010. Prior to the launch of V.A.C.® Therapy in Japan, patients with serious wounds faced extensive recovery times and painful wound redressing. Typical patients eligible for V.A.C.® Therapy in Japan include those with dehisced and hard-to-heal open wounds, as well as wounds following trauma, surgery, and amputation.

To date, KCI V.A.C.® Therapy1 has been used to treat more than seven million wounds worldwide and has been clinically proven in more than 25 randomized controlled trials and 795 peer-reviewed articles.2 Over 93 percent of published NPWT literature is KCI V.A.C.® Therapy-specific.2

For more information about KCI in Japan, please visit www.kcij.com.

About KCI

Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 25 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.

Footnotes

1. “V.A.C.® Therapy System” is the category covering two approved NPWT Products in Japan: ActiV.A.C.® Therapy System and V.A.C. ATS® Therapy System.

2. As of March 2013. KCI data on file.

CONTACT

KCI Corporate Communications
Sarah Swift, +44 (0)7970 742696
sswift@kci1.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表